EPCAM and neoplasm: Passive delivery of drug-loaded nanoparticles (i.e., the Enhanced Permeability and Retention, EPR, effect) is mainly due to fenestrated and immature new tumor vessels (128–131) while, the active delivery is due to a ligand-binding mechanism (e.g., nanoparticles targeting EpCAM, the folate receptor, EGFR and CD44) (132–134) (Figure 3).